
Oscar Bertetto

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/63755/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Comment on Medication-Related Osteonecrosis of the Jaw: MASCC/ISOO/ASCO Clinical Practice Guideline Summary. JCO Oncology Practice, 2020, 16, 142-145.	2.9	18
2	Variability of clinical target volume delineation for rectal cancer patients planned for neoadjuvant radiotherapy with the aid of the platform Anatom-e. Clinical and Translational Radiation Oncology, 2018, 11, 33-39.	1.7	20
3	Prospective phase II trial of neoadjuvant chemo-radiotherapy with Oxaliplatin and Capecitabine in locally advanced rectal cancer (XELOXART). Medical Oncology, 2013, 30, 581.	2.5	11
4	FOLFOX-4 Regimen or Single-agent Gemcitabine as First-line Chemotherapy in Advanced Biliary Tract Cancer. American Journal of Clinical Oncology: Cancer Clinical Trials, 2013, 36, 466-471.	1.3	17
5	Decreasing Frequency of Osteonecrosis of the Jaw in Cancer and Myeloma Patients Treated with Bisphosphonates: The Experience of the Oncology Network of Piedmont and Aosta Valley (North-Western Italy). ISRN Oncology, 2013, 2013, 1-8.	2.1	14
6	Hospital factors and patient characteristics in the treatment of colorectal cancer: a population based study. BMC Public Health, 2012, 12, 775.	2.9	16
7	The Effects of Reiki Therapy on Pain and Anxiety in Patients Attending a Day Oncology and Infusion Services Unit. American Journal of Hospice and Palliative Medicine, 2012, 29, 290-294.	1.4	50
8	Impact of initial pattern of care on hospital costs in a cohort of incident lung cancer cases. Journal of Evaluation in Clinical Practice, 2012, 18, 269-275.	1.8	2
9	Episodic (Breakthrough) Pain Prevalence in a Population of Cancer Pain Patients. Comparison of Clinical Diagnoses With the QUDEl—Italian Questionnaire for Intense Episodic Pain. Journal of Pain and Symptom Management, 2012, 43, 833-841.	1.2	62
10	Chemotherapy with or without low-dose interleukin-2 in advanced non-small cell lung cancer: results from a phase III randomized multicentric trial. International Journal of Oncology, 2011, 39, 1011-7.	3.3	25
11	Population-based analyses of radical cystectomy and urinary diversion for bladder cancer in northern Italy. BJU International, 2011, 108, E266-E271.	2.5	12
12	The impact of anemia on quality of life and hospitalisation in elderly cancer patients undergoing chemotherapy. Critical Reviews in Oncology/Hematology, 2011, 77, 70-77.	4.4	10
13	Osteonecrosis of the Jaw After Zoledronic Acid and Denosumab Treatment. Journal of Clinical Oncology, 2011, 29, e521-e522.	1.6	37
14	Factors affecting pattern of care and survival in a population-based cohort of non-small-cell lung cancer incident cases. Cancer Epidemiology, 2010, 34, 483-489.	1.9	46
15	Prospective, Multicenter, Randomized Trial of a New Organizational Modality for Providing Information and Support to Cancer Patients. Journal of Clinical Oncology, 2009, 27, 1794-1799.	1.6	17
16	Continuous 5-fluorouracil infusion plus long acting octreotide in advanced well-differentiated neuroendocrine carcinomas. A phase II trial of the Piemonte Oncology Network. BMC Cancer, 2009, 9, 388.	2.6	62
17	Predictors of treatment failures during chemotherapy: A prospective study on 110 older cancer patients. Archives of Gerontology and Geriatrics, 2009, 48, 222-226.	3.0	35
18	Effects of Transdermal Buprenorphine on Patients-reported Outcomes in Cancer Patients. Clinical Journal of Pain, 2009, 25, 671-682.	1.9	8

OSCAR BERTETTO

#	Article	IF	CITATIONS
19	Multicentric, Randomized Phase III Trial of Two Different Adjuvant Chemotherapy Regimens plus Three Versus Twelve Months of Trastuzumab in Patients with HER2-Positive Breast Cancer (Short-HER Trial;) Tj ETQq1	1 027484314	4 nggBT /Overi
20	Capecitabine versus Bolus Fluorouracil plus Leucovorin (Folinic Acid) as Adjuvant Chemotherapy for Patients with Dukes' C Colon Cancer. Clinical Drug Investigation, 2008, 28, 645-655.	2.2	28
21	Adjuvant Treatment of High-Risk, Radically Resected Gastric Cancer Patients With 5-Fluorouracil, Leucovorin, Cisplatin, and Epidoxorubicin in a Randomized Controlled Trial. Journal of the National Cancer Institute, 2007, 99, 601-607.	6.3	96
22	Activity of Weekly Paclitaxel in Advanced Hormone-Refractory Prostate Cancer. American Journal of Clinical Oncology: Cancer Clinical Trials, 2007, 30, 234-238.	1.3	6
23	Accessibility as a major determinant of radiotherapy underutilization: A population based study. Health Policy, 2007, 80, 483-491.	3.0	41
24	Predicting gefitinib responsiveness in lung cancer by fluorescence in situ hybridization/chromogenic in situ hybridization analysis of EGFR and HER2 in biopsy and cytology specimens. Molecular Cancer Therapeutics, 2007, 6, 1223-1229.	4.1	54
25	Autoantibody Signature in Human Ductal Pancreatic Adenocarcinoma. Journal of Proteome Research, 2007, 6, 4025-4031.	3.7	88
26	Gemcitabine plus Cisplatin versus Gemcitabine plus Carboplatin as First-Line Chemotherapy in Advanced Transitional Cell Carcinoma of the Urothelium: Results of a Randomized Phase 2 Trial. European Urology, 2007, 52, 134-141.	1.9	286
27	Specific Detection of Cytokeratin 20-Positive Cells in Blood of Colorectal and Breast Cancer Patients by a High Sensitivity Real-Time Reverse Transcriptase-Polymerase Chain Reaction Method. Journal of Molecular Diagnostics, 2006, 8, 105-112.	2.8	20
28	Pain in cancer. An outcome research project to evaluate the epidemiology, the quality and the effects of pain treatment in cancer patients. Health and Quality of Life Outcomes, 2006, 4, 7.	2.4	23
29	Fractionated dose of cisplatin (CDDP) and vinorelbine (VNB) chemotherapy for elderly patients with advanced non-small cell lung cancer: Phase II trial. Lung Cancer, 2006, 54, 353-357.	2.0	9
30	Second-line chemotherapy with weekly paclitaxel and gemcitabine in patients with small-cell lung cancer pretreated with platinum and etoposide: a single institution phase II trial. Cancer Chemotherapy and Pharmacology, 2006, 58, 203-209.	2.3	12
31	Nonmyeloablative allogeneic blood stem cell transplantation in patients with metastatic solid tumors. Hematology, 2006, 11, 171-177.	1.5	2
32	A multicenter, randomized, Phase II study of cisplatin, etoposide, and gemcitabine or cisplatin plus gemcitabine as first-line treatment in patients with poor-prognosis small cell lung carcinoma. Cancer, 2005, 103, 772-779.	4.1	10
33	Pretreatment Quality of Life and Functional Status Assessment Significantly Predict Survival of Elderly Patients With Advanced Non—Small-Cell Lung Cancer Receiving Chemotherapy: A Prognostic Analysis of the Multicenter Italian Lung Cancer in the Elderly Study. Journal of Clinical Oncology, 2005. 23. 6865-6872.	1.6	452
34	Mechanisms of spontaneous osteoclastogenesis in cancer with bone involvement. FASEB Journal, 2005, 19, 1-24.	0.5	88
35	Combination regimen of epirubicin, vinorelbine and 5-fluorouracil continuous infusion as first-line chemotherapy in anthracycline-naĀ ⁻ ve metastatic breast cancer patients. European Journal of Cancer, 2005, 41, 249-255.	2.8	8
36	Oral estramustine plus oral etoposide in the treatment of hormone refractory prostate cancer patients: A phase II study with a 5-year follow-up. Urologic Oncology: Seminars and Original Investigations, 2005, 23, 1-7.	1.6	11

OSCAR BERTETTO

#	Article	IF	CITATIONS
37	Sequential chemotherapy of cisplatin and vinorelbine followed by paclitaxel and gemcitabine in advanced non-small-cell lung cancer. Lung Cancer, 2005, 47, 269-275.	2.0	8
38	Single-Agent Gemcitabine in Previously Untreated Elderly Patients with Advanced Bladder Carcinoma: Response to Treatment and Correlation with the Comprehensive Geriatric. Oncology, 2004, 67, 27-32.	1.9	55
39	Pain Control with Zoledronic Acid in Patients with Breast Cancer and Metastatic Bone Disease. American Journal of Cancer, 2004, 3, 257-263.	0.4	4
40	A phase II trial of weekly paclitaxel and gemcitabine in non-small cell lung cancer patients previously treated with platinum and vinorelbine. Anticancer Research, 2004, 24, 2567-72.	1.1	7
41	Gemcitabine and vinorelbine as second-line treatment in patients with metastatic breast cancer: a phase II study. Cancer Chemotherapy and Pharmacology, 2003, 52, 147-152.	2.3	34
42	Chemotherapy for Elderly Patients With Advanced Non-Small-Cell Lung Cancer: The Multicenter Italian Lung Cancer in the Elderly Study (MILES) Phase III Randomized Trial. Journal of the National Cancer Institute, 2003, 95, 362-372.	6.3	768
43	PCR-Detectable Nonneoplastic Bcl-2/IgH Rearrangements Are Common in Normal Subjects and Cancer Patients at Diagnosis but Rare in Subjects Treated With Chemotherapy. Journal of Clinical Oncology, 2003, 21, 1398-1403.	1.6	35
44	Histopathological findings after preoperative chemo-radiotherapy in oral and oropharyngeal carcinoma. A study of 28 resected specimens. European Journal of Cancer Part B, Oral Oncology, 1993, 29, 113-117.	0.9	2
45	Phase II study of divided-dose vinblastine in advanced breast cancer patients. Cancer Chemotherapy and Pharmacology, 1988, 21, 65-7.	2.3	3
46	Phase II trial of VP16–213 in squamous cell carcinoma of the head and neck. European Journal of Cancer & Clinical Oncology, 1987, 23, 577.	0.7	0
47	Comparison of Methylprednisolone and Metoclopramide in the Prophylactic Treatment of CIS-Platin-Induced Nausea and Vomiting. Tumori, 1984, 70, 237-241.	1.1	6
48	TWO SUDDEN DEATHS DURING PROPHYLACTIC ANTIEMETIC TREATMENT WITH HIGH DOSES OF DOMPERIDONE AND METHYLPREDNISOLONE. Lancet, The, 1984, 324, 1336-1337.	13.7	42